Pharmacogenomics. 2012;13(13):1523-1535. 5-year survival for stage III and IV (%): carriers, 38.1; noncarriers, 24.5 Median survival: p = 0.002 5-year survival for stage III and IV: p < 0.001 [46 ...

Pharmacogenomics. 2012;13(13):1523-1535. 5-year survival for stage III and IV (%): carriers, 38.1; noncarriers, 24.5 Median survival: p = 0.002 5-year survival for stage III and IV: p < 0.001 [46 ...

The Amsterdam-based company recently received IVDR certification for other tests including one for phenylketonuria.

Researchers determined the clinical classification of more than 90% of potential BRCA2 variants of uncertain significance in ...

为解决传统 BRCA1 检测方法的局限，伊朗研究人员开展纳米材料基生物传感器用于乳腺癌诊断的研究。结果显示这类传感器有高灵敏度等优势。推荐科研读者阅读，助力探索乳腺癌诊断新方向。 在全球范围内，乳腺癌就像一个 “健康杀手”，严重威胁着人们的生命健康。2020 年，全球大约有 230 万新的乳腺癌病例，68.5 万人因乳腺癌离世。而且，不同国家的乳腺癌发病率和死亡率差异很大，比如比利时每 10 ...

MRC Holland recently announced that five SALSA MLPA assays for the detection of hereditary breast and ovarian cancer (HBOC) ...

A bill that would require private Idaho health insurers to cover supplemental breast cancer screenings for high-risk patients ...

BOISE — A bill that would require private Idaho health insurers to cover supplemental breast cancer screenings for high-risk ...

导语卵巢癌作为妇科三大恶性肿瘤之一，其病死率居首位，严重威胁女性生命健康。约 70% 的卵巢上皮癌患者确诊时已是晚期。新辅助化疗（NACT）和间歇性减瘤术（ICS）为该类患者提供了潜在治疗手段。然而，是否所有晚期卵巢癌患者均可接受 ...

AstraZeneca announced that its drug Lynparza (olaparib) has been approved for use in Scotland. The approval by the Scottish ...

Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.